top of page

Merck to acquire privately held biopahrmaceutical company Tilos Therapeutics

  • Writer: ipharmaservices
    ipharmaservices
  • Jun 10, 2019
  • 1 min read

Merck announced that it will acquire Tilos Therapeutics for $773 million and will make contingent milestone payments.

Tilos Therapeutics is involved in targeting TGF-beta complex, targeting autoimmune disorders, fibrosis and cancer.

Boehringer Ingelheim Venture Fund and Partners Innovation Fund founded Tilos Therapeutics. ShangPharma provided additional innovation fund.


TGF-beta and LAP:

TGF-beta is a cytokine. It is expected to have a major role in the development of cancer and fibrosis. Along with protein, it forms latency associated peptide. TGF-beta blockers prevent the release of TGF-beta from LAP resulting in reduced TGF-beta activity.

Recent Posts

See All

Comments


For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

Find the latest pharma and healthcare news on Telegram now. Simply scan the QR code. 

Rephrase with Ginger (Cmd+⌥+E)
iPharmaCenter Telegran_edited.jpg
bottom of page